GBLX - GB Sciences, Inc.
| Previous Close | 0.2594 |
| Open | 0.2628 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2557 - 0.3189 |
| 52 Week Range | 0.2100 - 1.5600 |
| Volume | 5,238,377 |
| Avg. Volume | 684,715 |
| Market Cap | 53.74M |
| Beta | -1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1720 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•5 days ago
GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year
For the three months that ended June 30, 2018, GB Sciences, Inc. (GBLX) reported revenue of $1,315,284 and gross profit of $734,719. This compares to revenue and gross profit of $69,100 and $54,099, respectively, for the same period the prior year. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
- PR Newswire•14 days ago
Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences' Cannabis-Containing Complex Formulas for Parkinson's Disease in preparation for their clinical trial. LAS VEGAS, Aug. 6, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski will study the toxicology, anti-inflammatory properties, and immunomodulatory activity of GB Sciences' proprietary cannabis-based neuroprotective compounds using a diverse array of assays employing human primary white blood cells.
- PR Newswire•18 days ago
GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"
This pioneering research article explains the benefits of cannabinoid-based medicines for heart disease therapies based on scientific research. LAS VEGAS, Aug. 2, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including Dr. Alexander Stokes, President of Makai Biotechnology, LLC, and Dr. Helen Turner, VP of Innovation and Dean of the Division of Natural Sciences and Mathematics at Chaminade University, in expounding on this very important subject in "Cannabinoids, the Heart of the Matter".
- GlobeNewswire•20 days ago
GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance
GB Sciences, Inc (GBLX) has contracted Adherence Compliance, a leading cannabis compliance software and services firm, for its Chief Compliance Officer Program and Adherence SCORE App (a leading cannabis industry compliance inspection tool) to strengthen overall compliance in all U.S. markets where GB Sciences is currently operating or planning to initiate operations. “GB Sciences is continually focused on strengthening our enterprise compliance, especially given our aggressive expansion plans and the constantly changing regulatory landscape” said Dr. Dominick Monaco, VP Operations for GB Sciences.
- PR Newswire•last month
GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market
The first six proprietary strains are being cultivated by The Colorado Hemp Project and will serve as the basis for fresh revenue streams from both retail sales and raw ingredients for cannabis-based medical formulations. LAS VEGAS, July 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) updates the progress in their efforts to identify, cultivate and extract full spectrum hemp oil from proprietary hemp strains that contain desirable ratios of CBD, cannabinoids and terpenes to provide the necessary compounds to support both the Company's medical Intellectual Properties portfolio and open a fresh revenue stream in the rapidly growing retail hemp market. The search for a full spectrum hemp oil product that matched the quality and consistency of their cannabis genetics led GB Sciences to The Colorado Hemp Project.
- PR Newswire•last month
GB Sciences One of Ten Companies Named in Important New Canadian Research Publication
LAS VEGAS, July 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) was named as one of the ten select cannabis companies in North America according to a study conducted by a leading investment banking firm in their June 20, 2018 Industry Report on Medical Cannabis. GB Sciences was the only U.S. publicly traded company to make the list of ten companies.
- GlobeNewswire•2 months ago
GB Sciences Files Patent on Cannabis-based Therapies for the Treatment of Asthma, Urinary Cystitis, Hearing Loss, plus Chronic, Inflammatory and Neuropathic Pain
GB Sciences, Inc. (GBLX) has filed a new provisional patent application on the use of cannabis-based therapies for the manipulation of cannabis-sensitive ion channels in sensory neurons that contribute to chronic inflammatory pain conditions, peripheral neuropathy, urinary cystitis, asthma, and specific types of hearing loss. The GB Sciences drug development team believes that these new cannabis-based treatments could well herald the dawning of ‘individualized medicines’ from the cannabis plant by re-establishing balance in each individual patient’s endocannabinoid system. “Manipulating the TRP channels in sensory neurons could provide much needed relief for patients who are suffering from chronic pain, asthma, urinary cystitis, or hearing loss,” explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences.
- PR Newswire•2 months ago
GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain
The nonprovisional patent applications protect formulations for pain and heart disease therapies based on myrcene-containing complex mixtures. LAS VEGAS , June 25, 2018 /PRNewswire/ -- GB Sciences, Inc. ...
- GlobeNewswire•3 months ago
GB Sciences Puts Its Grey Matter To Work Solving The Big Green Riddle...
For large scale adoption of Cannabis in medical formulations the quality, consistency and trust in the raw ingredients is essential in providing a true scientific base line and prove efficacy in the medical world. “This technique allows us to produce healthy, genetically identical copies of prime mother plants resulting in optimal cannabinoid and terpene profiles over multiple grow cycles.
- PR Newswire•3 months ago
GB Sciences Will Now Serve A Greatly Expanded Patient Base In Louisiana With The Addition Of Autism, Glaucoma, Parkinson's, PTSD, Intractable Pain And Severe Muscle Spasms To The List Of Ailments Covered By Medical Cannabis Legislation
LAS VEGAS, May 22, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), it all started with one woman's plea and ended with a call to action for a dramatic expansion of diseases treated by medical cannabis throughout the State of Louisiana. The passage of the Alison Neustrom Act in 2015 opened the door for a relatively small number of qualified patients to legally receive medical marijuana treatment. The passage of two new House Bills increases the patient count to include patients with additional qualifying disease conditions in the State.
- PR Newswire•3 months ago
GB Sciences' Acquisition Of NevadaPURE Is Terminated
LAS VEGAS, May 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), the previously announced proposed acquisition of NevadaPURE, LLC, a Nevada limited liability company, by GB Sciences has been terminated. In accordance with the terms of the non-binding letter of intent signed between the parties and after the due diligence period (which was mutually extended by one week), GB Sciences and NevadaPURE, LLC mutually agreed not to proceed with the transaction. GB Sciences' Chairman of the Board and CEO John Poss said: "A nondisclosure agreement between the parties prevents GB Sciences from making extensive comments on the proposed transaction.
- ACCESSWIRE•3 months ago
Marijuana Stocks for Investors in the Free Cannabis Investor Magazine
MIAMI, FL / ACCESSWIRE / May 7, 2018 / Cannabis Investor Magazine , the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced ...
- ACCESSWIRE•4 months ago
GB Sciences is Exploring a Cannabis Therapy for Parkinson's, Analysts Review
The company recently announced that it is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease. The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. Furthermore, the transaction also enables GB Sciences with access to three licenses from the state of Nevada for cultivation and production of marijuana along with the one for running a dispensary.
- ACCESSWIRE•4 months ago
GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018
DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...
- PR Newswire•4 months ago
Exploratory IND Is Planned Using GB Sciences' Proprietary Mixtures of Botanical Compounds to Provide the Highest Efficacy for Patients
LAS VEGAS, April 17, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), as previously reported, plans to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data, to support clinical development decisions on prioritizing among multiple, related Parkinson's Disease ("PD") formulations. GB Sciences has a patent application covering multiple, related PD-formulas that are based on complex mixtures of minor cannabinoids and terpenes from cannabis chemovars. In preclinical studies, GB Sciences has demonstrated that complex mixtures of cannabis-based compounds may provide greater clinical benefits than single compound treatments due to molecular synergies for the treatment of Parkinson's.
- PR Newswire•4 months ago
GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease
LAS VEGAS, April 10, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD"). The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. An Exploratory IND requires less pre-clinical data and offers a more flexible way to get essential information about potential drug development candidates than a more conventional early phase development program. Performing an FDA-Registered clinical trial, instead of a Nevada-based pilot trial as reported earlier, also translates to quicker entry into international markets with harmonized regulatory standards.
- PR Newswire•5 months ago
GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula
LAS VEGAS, April 4, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has completed the technology transfer for the manufacturing of time-released nanoparticles containing a cannabinoid-based therapeutic for neuropathic pain from the University of Seville. As announced in Q4 of 2017, GB Sciences has obtained the exclusive worldwide license to the intellectual property covering this time-released cannabinoid formulation from the University of Seville ("USE"), the Centro de Investigación Biomédica en Red de Salud Mental ("CIBERSAM") and the University of Cadiz ("UCA").
- PR Newswire•5 months ago
GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
LAS VEGAS, March 28, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is extremely pleased to announce it has signed a letter of intent to purchase 100% of the ownership interests of NevadaPURE's Las Vegas operation for $28 million in cash and the assumption of approximately $5 million of outstanding liabilities. The annualized sales run rate of NevadaPURE is over $16 million based on its performance since adult use became legal in Nevada, making the purchase price only two times sales. This sales multiple compares with GB's current price-to-annualized-sales multiple of 16, and a typical multiple of 60 or much more for publicly traded cannabis companies whose sales are similar to GB's.
CNW Group•5 months agoGB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
- PR Newswire•5 months ago
Research Projects Sales of Legal Cannabis Products to Accelerate This Year
According to a report by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is estimated to grow at a CAGR of 21.1% between 2017 to 2024, while reaching a value of $63.5 billion by 2024. The market is going through a period of robust growth because of increasing legalization and decriminalization of cannabis products across North America. Data by Arcview Market Research clarifies that growth of the legal cannabis industry are expected reaccelerate in 2018, as adult use sales ramp up in Canada, California, and Massachusetts along with medical sales in Florida.
- PR Newswire•5 months ago
GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium
LAS VEGAS, March 15, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce their sponsorship of the 1st Annual "Innovation in Medical Cannabis Therapies" Symposium in Las Vegas, Nevada, on Friday, June 1st, 2018. Top innovators in cannabis tech, biotech, nanotech, and metabolomics are invited to this collaborative discussion, which was designed to explore the necessary advances across multiple fields that are required for the development of safe and effective plant-based medicines. The GBS approach to research is always grounded in solid science and The Life Sciences team, a division of GB Sciences, has discovered that other researches who ascribe to this nontraditional mindset usually find funding and partnering difficult to come by.
- CNW Group•5 months ago
GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium
GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium
- CNW Group•6 months ago
GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project
GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project
- PR Newswire•6 months ago
GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project
LAS VEGAS, Feb. 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce a new agreement with the Colorado Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in proprietary CBD formulations. The mission statement of the Colorado Hemp Project is: an organic hemp farm consulting agency that works with local farmers and municipalities across the globe to bring hemp cultivars and resources to the communities that need it the most, with the sole intention of healing the planet by accelerating the establishment of local, sustainable hemp farms and companies everywhere. GB Sciences believes that hemp will provide an important palette upon which important compounds can be created, and believes that, ultimately, hemp will provide a relatively inexpensive source of important and beneficial cannabinoids.